KEY TAKEAWAYS
- The study aimed to investigate the impact of metastasis sites on OS, DRFS, and post-relapse survival in TNBC.
- Researchers concluded that TNBC patients with multiple metastasis and CNS involvement face a higher risk of death compared to those with bone metastasis, emphasizing the critical impact on OS.
Evidence on triple-negative breast cancer (TNBC) survival differences based on metastasis sites is limited. Luis Piedra-Delgado and her team aimed to analyze overall survival (OS), distant relapse-free survival (DRFS), and survival since the diagnosis of the relapse (MS), according to the metastasis side.
Researchers performed an inclusive analysis through a retrospective study involving TNBC patients with distant metastases at the Instituto Nacional de Enfermedades Neoplasicas. Prognostic factors were discerned using multivariate Cox regression analysis.
About 309 patients were included in the study. Visceral metastasis constituted 41%, with the lung being the most frequent initial metastatic site (33.3%). Over a median 10.2-year follow-up, the 5-year DRFS and OS stood at 10% and 26%, respectively. Prognostic factors for OS included N staging (N2-N3 vs. N0, HR = 1.49, 95% CI: 1.04-2.14), visceral metastasis (vs. bone; HR = 1.55, 95% CI: 0.94-2.56), central nervous system metastasis (vs. bone; HR = 1.88, 95% CI: 1.10-3.22), and multiple metastasis sites (vs. bone; HR = 2.55, 95% CI: 1.53-4.25). Multiple metastasis was a predictor of MS (HR = 2.30, 95% CI: 1.42-3.72). Notably, DRFS showed no variations based on metastasis type or solid organ involvement.
The study concluded that TNBC patients with multiple metastases, particularly in the central nervous system, face an elevated risk of death compared to those with bone metastasis, impacting both OS and post-relapse survival (MS).
No funding was provided for the study.
Source: https://pubmed.ncbi.nlm.nih.gov/38300959/
Piedra-Delgado L, Chambergo-Michilot D, Morante Z,et.al (2024). “Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.” PLoS One. 2024 Feb 1;19(2):e0293833. doi: 10.1371/journal.pone.0293833. PMID: 38300959; PMCID: PMC10833533.
